Antiviral Activity of the Human Immunodeficiency Virus Type 1–Specific Nonnucleoside Reverse Transcriptase Inhibitor HBY 097 Alone and in Combination with Zidovudine in a Phase II Study

Autor:	Thomas C. Merigan, A Dunkler, Jan Balzarini, D Oette, J P Kleim, Irvin Winkler, J R Suarez, Mark A. Winters, Gunther Riess
Rok vydání:	1999
Předmět:	biology Reverse-transcriptase inhibitor Combination therapy biology.organism_classification Virology Reverse transcriptase Virus Zidovudine Infectious Diseases parasitic diseases Lentivirus medicine Immunology and Allergy Sida Viral load medicine.drug
Zdroj:	The Journal of Infectious Diseases. 179:709-713
ISSN:	1537-6613 0022-1899
Popis:	The safety and antiviral activity of the second-generation nonnucleoside inhibitor HBY 097 was investigated in asymptomatic or mildly symptomatic human immunodeficiency virus (HIV)-1-infected patients in a randomized, double-blinded, dose-escalation study. Mean maximum virus load decreases ranged from -1.31 log10 copies/mL of plasma at week 1 in the group receiving HBY 097 monotherapy (250 mg three times daily) to -2.19 log10 copies/mL at week 4 in the group receiving zidovudine plus HBY 097 (750 mg three times daily). After 12 weeks, these patients had viral RNA copy numbers 1.05 log10 below baseline. Genotypic analysis of resistance development revealed reverse transcriptase K103N variants in most patients, which was associated with less durable efficacy of HBY 097 treatment. Fewer patients receiving combination therapy with high-dose HBY 097 developed the K103N variant (P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::cb30686ff5e3bba4a827e9ddfd6371de https://doi.org/10.1086/314633 Zobrazit plný text záznamu